COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
Chiara Agrati, Serena Di Cosimo, Daniela Fenoglio, Giovanni Apolone, Fabio Ciceri, Gennaro Ciliberto, Fausto Baldanti, Massimo Costantini, Diana Giannarelli, Giuseppe Ippolito, Franco Locatelli, Alberto Mantovani, Aldo Morrone, Fabrizio Tagliavini, Antonio Uccelli, Pier Luigi Zinzani, Nicola Silvestris, María Rescigno
Abstract
, fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.